François Mercier

Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study

Krzysztof Selmaj, David K.B. Li, Hans-Peter Hartung et al. · The Lancet Neurology · 2013 · 233 citations

Pharmacy, Neurology, Pharmacotherapy +7

Neutrophil-to-lymphocyte ratio as a prognostic biomarker for men with metastatic castration-resistant prostate cancer receiving first-line chemotherapy: data from two randomized phase III trials

Robert J. van Soest, Arnoud J. Templeton, Francisco Vera-Badillo et al. · Annals of Oncology · 2014 · 141 citations · Full text

Medicine, Immunology, Oncology +17

Adherence to monthly and weekly oral bisphosphonates in women with osteoporosis

FE Cotté, Patrice Fardellone, François Mercier et al. · Osteoporosis International · 2009 · 138 citations · Full text

Pharmacy, Pharmacotherapy, Pharmaceutical Care +13

Temporal profile of lymphocyte counts and relationship with infections with fingolimod therapy

G. Francis, Ludwig Kappos, Paul O’Connor et al. · Multiple Sclerosis Journal · 2013 · 134 citations

Life Sciences, Immunology, Pharmacotherapy +15

BIPNOR: A New, Efficient Bisphosphine Having Two Chiral, Nonracemizable, Bridgehead Phosphorus Centers for Use in Asymmetric Catalysis

Frédéric Robin, François Mercier, Louis Ricard et al. · Chemistry - A European Journal · 1997 · 127 citations

Natural Sciences, Chemistry, Catalysis +11